Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 64.08 |
| Open | 62.69 |
| Bid | 64.23 x 400 |
| Ask | 64.29 x 400 |
| Day's range | 62.07 - 64.30 |
| 52-week range | 62.07 - 87.87 |
| Volume | |
| Avg. volume | 7,041,752 |
| Market cap | 80.071B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 178.53 |
| EPS (TTM) | 0.36 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.08 (4.79%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | 81.21 |
- Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif., June 01, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). The
ZacksGilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
FOSTER CITY, Calif., May 31, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previou
